Complex Oncological Center - Shumen EOOD — Clinical Trial Site

10 Registered trials

4 Currently recruiting

Organisation

Complex Oncological Center - Shumen EOOD

Location

Shumen, Bulgaria

Identifier

ORG-100042720

Address

Ulitsa Vasil Aprilov 63, 9705, Bulgaria

Departments

Departement of Medical Oncology
Department of medical oncology
Medical Oncology
Medical oncology department

Clinical trials at this site (10)

Search interface

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label … Ended

2023-503214-68-00 metastatic breast cancer 4 2024-01-31
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended

2024-510809-28-00 Metastatic Castration-sensitive Prostate Cancer 5 2021-09-27
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT… Ended

2023-510446-24-00 Cancer cachexia 4 2023-05-30
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5